Zealand Pharma, Generate strike obesity drug deal worth up to $1.2 billion, Bloomberg News reports
13/10/2026 21:27
Zealand Pharma, Generate strike obesity drug deal worth up to $1.2 billion, Bloomberg News reports Oct 13 (Reuters) - Danish drugmaker Zealand Pharma ZELA.CO and Generate Biomedicines GENB.O have struck a deal worth up to nearly $1.2 billion to develop obesity treatments using artificial intelligence, Bloomberg News reported on Tuesday.
The agreement includes $30 million upfront and $35 million in early milestone payments, Bloomberg reported, citing a document.
Zealand Pharma did not did not immediately respond to a Reuters request for comment.
(Reporting by Sahil Pandey in Bengaluru)
Recent news on Generate Biomedicines
See all newsZealand Pharma, Generate strike AI obesity drug deal worth up to $1.2 billion (updated)
Brief: Generate Biomedicines And Zealand Pharma Enter Collaboration And License Agreement To Develop Protein Therapeutics Engineered With Ai For Metabolic Diseases
Zealand Pharma, Generate strike obesity drug deal worth up to $1.2 billion, Bloomberg News reports
Brief: Zealand Pharma Makes Deal With Generate Worth Up To $1.2 Billion - Bloomberg News
Brief: Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial Of ‘Armored’ Car T Therapy For Ovarian Cancer